A | B | |
---|---|---|
9 | ADHD/Narcolepsy - Stimulants | Clonidine ER - Kapvay® Guanfacine ER - Intuniv® |
10 | ||
11 | Clonidine IR - Catapres® Clonidine Patch - Catapres-TTS® Guanfacine IR - Tenex® Note - Diagnosis is only required for clonidine IR, clonidine patch and guanfacine IR if the recipient is younger than 21 years of age | |
12 |
Guanfacine Description Guanfacine tablets, USP are a centrally acting antihypertensive with α 2 -adrenoceptor agonist properties in tablet form for oral administration. The chemical name of Guanfacine hydrochloride is N-amidino-2- (2,6-dichlorophenyl) acetamide monohydrochloride and its molecular weight is 282.55. Its structural formula is:
Guanfacine is contraindicated in patients with a history of a hypersensitivity reaction to Guanfacine extended-release tablets or its inactive ingredients, or other products containing Guanfacine. Rash and pruritus have been reported.
Guanfacine tablets, USP are indicated in the management of hypertension. Guanfacine may be given alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. Guanfacine tablets, USP are contraindicated in patients with known hypersensitivity to Guanfacine hydrochloride, USP.
Adverse Reactions. Adverse reactions noted with Guanfacine are similar to those of other drugs of the central α 2 adrenoreceptor agonist class: dry mouth, sedation (somnolence), weakness (asthenia), dizziness, constipation, and impotence. While the reactions are common, most are mild and tend to disappear on continued dosing.
F90. 1, Attention-deficit hyperactivity disorder, predominantly hyperactive type.
ICD-10 Code for Other long term (current) drug therapy- Z79. 899- Codify by AAPC.
Other specified counselingICD-10 code Z71. 89 for Other specified counseling is a medical classification as listed by WHO under the range - Factors influencing health status and contact with health services .
Z03.89ICD-10-CM Codes that Support Medical Necessity For monitoring of patient compliance in a drug treatment program, use diagnosis code Z03. 89 as the primary diagnosis and the specific drug dependence diagnosis as the secondary diagnosis.
ICD-10 Code for Encounter for issue of repeat prescription- Z76. 0- Codify by AAPC.
The ICD-10 section that covers long-term drug therapy is Z79, with many subsections and specific diagnosis codes.
The patient's primary diagnostic code is the most important. Assuming the patient's primary diagnostic code is Z76. 89, look in the list below to see which MDC's "Assignment of Diagnosis Codes" is first.
Preventative medicine counselingCPT 99401: Preventative medicine counseling and/or risk factor reduction intervention(s) provided to an individual, up to 15 minutes may be used to counsel commercial members regarding the benefits of receiving the COVID-19 vaccine.
Z codes are for use in any healthcare setting. Z codes may be used as either a first-listed (principal diagnosis code in the inpatient setting) or secondary code, depending on the circumstances of the encounter.
CPT® 80307, Under Presumptive Drug Class Screening Procedures. The Current Procedural Terminology (CPT®) code 80307 as maintained by American Medical Association, is a medical procedural code under the range - Presumptive Drug Class Screening Procedures.
10 for Other psychoactive substance abuse, uncomplicated is a medical classification as listed by WHO under the range - Mental, Behavioral and Neurodevelopmental disorders .
b. Drug confirmation testing is considered included in CPT codes 80305 – 80307 and HCPCS codes G0480 – G0483, G0659, and is not eligible for separate reimbursement.
The chemical name of Guanfacine hydrochloride, USP is N-amidino-2- (2,6-dichlorophenyl) acetamide hydrochloride and its molecular weight is 282.56. Its structural formula is: Guanfacine hydrochloride, USP is a white to off-white powder; sparingly soluble in water and alcohol and slightly soluble in acetone. Each tablet, for oral administration, ...
Guanfacine tablets, USP are available in 2 tablet strengths of Guanfacine (as the hydrochloride salt) as follows: 1 mg: white, oval, flat-faced, beveled-edge tablet with “AN” on one side and “711” on the other side. They are available as follows: Bottles of 100: NDC 42291-310-01.
By stimulating these receptors, Guanfacine reduces sympathetic nerve impulses from the vasomotor center to the heart and blood vessels. This results in a decrease in peripheral vascular resistance and a reduction in heart rate.
An open-label postmarketing study involving 21,718 patients was conducted to assess the safety of Guanfacine hydrochloride 1 mg/day given at bedtime for 28 days. Guanfacine hydrochloride was administered with or without other antihypertensive agents. Adverse events reported in the postmarketing study at an incidence greater than 1% included dry mouth, dizziness, somnolence, fatigue, headache and nausea. The most commonly reported adverse events in this study were the same as those observed in controlled clinical trials.
Relative to an intravenous dose of 3 mg, the absolute oral bioavailability of Guanfacine is about 80%. Peak plasma concentrations occur from 1 to 4 hours with an average of 2.6 hours after single oral doses or at steady-state.
In individuals with normal renal function, Guanfacine and its metabolites are excreted primarily in the urine. Approximately 50% (40 to 75%) of the dose is eliminated in the urine as unchanged drug; the remainder is eliminated mostly as conjugates of metabolites produced by oxidative metabolism of the aromatic ring.
No carcinogenic effect was observed in studies of 78 weeks in mice at doses more than 150 times the maximum recommended human dose and 102 weeks in rats at doses more than 100 times the maximum recommended human dose. In a variety of test models, Guanfacine was not mutagenic.
Poisoning by caffeine, intentional self-harm 1 T43.612 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail. 2 The 2021 edition of ICD-10-CM T43.612 became effective on October 1, 2020. 3 This is the American ICD-10-CM version of T43.612 - other international versions of ICD-10 T43.612 may differ.
Use secondary code (s) from Chapter 20, External causes of morbidity, to indicate cause of injury. Codes within the T section that include the external cause do not require an additional external cause code.
This medication is used alone or with other medications to treat high blood pressure (hypertension).
May Treat: Hypertension · Attention-deficit hyperactivity disorder
Brand Names: Tenex · Intuniv ER
Drug Class: Attention Deficit-Hyperact. Disorder (ADHD)- alpha-2 Receptor Agonist · Central Alpha-2 Receptor Agonists
Availability: Prescription Required
Pregnancy: Consult a doctor before using
May Treat: Hypertension · Attention-deficit hyperactivity disorder
Brand Names: Tenex · Intuniv ER
Drug Class: Attention Deficit-Hyperact. Disorder (ADHD)- alpha-2 Receptor Agonist · Central Alpha-2 Receptor Agonists
Availability: Prescription Required
Pregnancy: Consult a doctor before using
Lactation: Consult a doctor before using
Alcohol: Limit intake while taking this medication
Driving: May cause drowsiness or dizziness. Use caution